ReviewActa bio-medica : Atenei Parmensis2019
Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis.
Review in Acta bio-medica : Atenei Parmensis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Photodistributed Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and proposal for a new diagnostic classification.European journal of medical research · 2023Pooled it
- Diagnosis and Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Patients: A Systematic Review of Clinical Guidelines and Consensus Statements.Pediatric dermatologyPooled it
- Angioedema: a rare manifestation of Henoch-Schönlein purpura.BMJ case reports · 2026Article
- Trimethoprim/Sulfamethoxazole-Induced Systemic Toxic Epidermal Necrolysis Syndrome: A Case Report.Clinical case reports · 2026Article
- Pharmacovigilance of paracetamol-induced Stevens-Johnson Syndrome and toxic epidermal necrolysis in the Indian population.Indian journal of pharmacology · 2026Article
- Evaluation of drug causality in SJS/TEN: The role of the lymphocyte transformation test and conventional/modified IFN-γ ELISpot assays.The World Allergy Organization journal · 2026Article
- A Systematic Review of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Epidemiology and Treatment Strategies.International journal of general medicine · 2026Review
- Diagnostic Challenges in a Pediatric Case of Recurrent Blistering Skin Reactions: Ibuprofen-Induced Fixed Drug Exanthema versus Infection-Triggered Erythema Multiforme.Drug, healthcare and patient safety · 2026Article
- Paediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: patterns and outcomes in a retrospective Pakistani cohort.BMJ paediatrics open · 2025Article
- Drug hypersensitivity reactions in children in clinical practice: A WAO Statement.The World Allergy Organization journal · 2025Review
- Cefuroxime-induced toxic epidermal necrolysis in a 4-year-old male child: a case report.Annals of medicine and surgery (2012) · 2025Article
- Challenges in Diagnosing and Treatment of Pediatric Necrotic Skin Conditions: A Retrospective Study.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Clinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome / toxic epidermal necrolysis.Investigational new drugs · 2025Article
- Advances in pediatrics in 2023: choices in allergy, analgesia, cardiology, endocrinology, gastroenterology, genetics, global health, hematology, infectious diseases, neonatology, neurology, pulmonology.Italian journal of pediatrics · 2024Review
- COVID-19 and severe cutaneous allergic reactions to sulfonamides.Allergy and asthma proceedings · 2024Article
- Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management.American journal of clinical dermatology · 2024Review
- Coronavirus-disease-2019-associated Stevens-Johnsons syndrome in a 15-year-old boy: a case report and review of the literature.Journal of medical case reports · 2024Review
- Risk factors for drug hypersensitivity reactions in children.Italian journal of pediatrics · 2024Review
- Stevens-Johnson syndrome associated with pancytopenia: a case report.Annals of medicine and surgery (2012) · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be considered a late-onset allergic reaction, can cause serious long-term sequelae. SJS/TEN are considered a spectrum of life-threatening adverse drug reactions. They have the same clinical manifestations and the only difference is in the extent of epidermal detachment. These conditions are associated with high mortality, although incidence of SJS/TEN is rare in children. SJS/TEN is an adverse drug reaction influenced by genes that involve pharmacokinetics, pharmacodynamics and immune response. Infective agents are additional influencing factors. Anticonvulsants and antibiotics, and especially sulphonamides and non-steroidal anti-inflammatory drugs, are among the drugs that were predominantly suspected of triggering SJS/TEN. No evidence-based standardized treatment guidelines for SJS or TEN are currently available. The usual treatment is mainly founded on the withdrawal of the suspected causative agent and supportive therapy. In pediatric patients, the specific therapeutic strategies are controversial and comprise systemic corticosteroids and the use of intravenous immunoglobulin (IVIG). More recently, new therapeutic approaches have been used, such as immunosuppressive therapies, including cyclosporine and TNF-α inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.